Related Experiment Video

Updated: Sep 26, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K

An IL-2 Protein Therapeutic for Cancer that Gains Function on the Spot

Daniel-Adriano Silva1,2

  • 1Monod Bio, Inc, Seattle, Washington.

Cancer Immunology Research
|April 18, 2022
PubMed

Insights

Engineered interleukin-2 (IL-2) prodrug WTX-124 shows promise for cancer treatment by activating within the tumor microenvironment, minimizing severe systemic toxicities associated with traditional recombinant human IL-2 (rhIL-2) therapy.

Area of Science:

  • Immunotherapy
  • Drug Development
  • Oncology

Background:

  • Recombinant human interleukin-2 (rhIL-2) has limited clinical use in cancer due to severe systemic toxicities.
  • Developing targeted immunotherapies is crucial for improving cancer treatment efficacy and patient safety.

Discussion:

  • Nirschl and colleagues developed WTX-124, an engineered IL-2 prodrug designed for tumor-specific activation.
  • This prodrug aims to concentrate therapeutic effects within the tumor microenvironment, reducing off-target side effects.
  • Preclinical characterization of WTX-124 demonstrates its potential to overcome the toxicity limitations of conventional rhIL-2.

Key Insights:

  • WTX-124 is engineered to be inactive systemically but activated preferentially within the tumor microenvironment.
  • Preclinical data suggest WTX-124 exhibits significantly reduced systemic toxicity compared to rhIL-2.
  • The prodrug approach offers a novel strategy for enhancing the therapeutic index of IL-2 in cancer treatment.

Outlook:

  • Further clinical translation of WTX-124 is anticipated.
  • This engineered IL-2 prodrug represents a promising advancement in cancer immunotherapy.
  • The success of WTX-124 could pave the way for similar targeted prodrug strategies in oncology.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
689
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K